Prostate Cancer Clinical Trials in New Orleans, Louisiana

6 studies are recruiting for prostate cancer in New Orleans, Louisiana right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Sacral Neuromodulation for Male Overactive Bladder (MOAB)

   To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Louisiana State University, New Orleans, Louisiana

   Locations

   23 in total

   Run by

   Axonics, Inc.

   See if you can join NCT06511141 on ClinicalTrials.gov

2. A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

   Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ochsner Health - Ochsner Medical Center - New Orleans, New Orleans, Louisiana

   Locations

   54 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT07005154 on ClinicalTrials.gov

3. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

   The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Tulane Medical Center, New Orleans, Louisiana

   Locations

   57 in total

   Run by

   Amgen

   See if you can join NCT04221542 on ClinicalTrials.gov

4. PSMA PET Combined With MRI for the Detection of PCa

   This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ochsner Clinic Foundation, New Orleans, Louisiana

   Locations

   18 in total

   Run by

   Telix Pharmaceuticals (Innovations) Pty Limited

   See if you can join NCT07052214 on ClinicalTrials.gov

5. Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

   The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as …

   Stage

   Phase 4

   Ages

   18 to 100

   Site

   Tulane Cancer Center, New Orleans, Louisiana

   Locations

   54 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT05803941 on ClinicalTrials.gov

6. International Registry for Men With Advanced Prostate Cancer (IRONMAN)

   Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry an…

   Stage

   Not phased

   Ages

   21 and older

   Site

   Tulane University, New Orleans, Louisiana

   Locations

   121 in total

   Run by

   Prostate Cancer Clinical Trials Consortium

   See if you can join NCT03151629 on ClinicalTrials.gov